MedAlliance develops next‑generation drug‑coated balloon (DCB) technology, Selution, a sirolimus micro‑reservoir DCB intended for peripheral artery disease (PAD), coronary artery disease (CAD) and arteriovenous fistulas (AVF). The micro‑reservoir design is intended to deliver controlled, sustained release of sirolimus to target lesions and to enable movement away from permanent metal scaffolds and durable polymers. Early clinical data from a first‑in‑man study reported one of the lowest six‑month target lesion revascularization rates seen in a DCB first‑in‑man study. The company is privately owned, was founded in 2008, and has R&D facilities in Irvine, California and Singapore. MedAlliance has a team with prior experience in drug‑eluting stents, balloons, polymers and drugs and focuses on product development and commercialization in coronary and peripheral vascular disease.

Total raised

$20M

Funding rounds

1

Latest round

Equity

Latest activity

May 2018